作者
Celalettin Ustun, Jennifer Le-Rademacher, Hai-Lin Wang, Megan Othus, Zhuoxin Sun, Brittny Major, Mei-Jie Zhang, Elizabeth Storrick, Jacqueline M Lafky, Selina Chow, Krzysztof Mrózek, Eyal C Attar, Such Nand, Clara D Bloomfield, Larry D Cripe, Martin S Tallman, Frederick Appelbaum, Richard A Larson, Guido Marcucci, Gail J Roboz, Geoffrey L Uy, Richard M Stone, Aminah Jatoi, Thomas C Shea, Marcos de Lima, James M Foran, Brenda M Sandmaier, Mark R Litzow, Harry P Erba, Arti Hurria, Daniel J Weisdorf, Andrew S Artz
发表日期
2019/11
期刊
Leukemia
卷号
33
期号
11
页码范围
2599-2609
出版商
Nature Publishing Group
简介
The preferred post-remission therapy for older patients with acute myeloid leukemia (AML) in first complete remission (CR1) remains uncertain. In this retrospective, multicenter study, we compared the outcomes for older AML patients (age 60–77 years) receiving allogeneic hematopoietic cell transplantation (alloHCT) (n = 431) with those treated on prospective National Clinical Trials Network induction and nontransplantation chemotherapy (CT) consolidation trials (n = 211). AlloHCT patients were younger (median age: 64.2 versus 67.9 years, p < 0.001), but more frequently had high-risk AML (high WBC, secondary AML, and unfavorable cytogenetics). Overall survival (OS) was worse in alloHCT during the first 9 months after CR1 (HR = 1.52, p = 0.02), but was significantly better thereafter (HR = 0.53, p < 0.0001) relative to CT. Treatment-related mortality (TRM) following HCT was worse in the first 9 …
学术搜索中的文章
C Ustun, J Le-Rademacher, HL Wang, M Othus, Z Sun… - Leukemia, 2019